ID   NOMO-1
AC   CVCL_1609
SY   Nomo-1; NOMO1
DR   BTO; BTO:0005916
DR   CLO; CLO_0009851
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 398
DR   BioSample; SAMN01821652
DR   BioSample; SAMN01821737
DR   BioSample; SAMN03473105
DR   BioSample; SAMN10988550
DR   cancercelllines; CVCL_1609
DR   Cell_Model_Passport; SIDM00580
DR   ChEMBL-Cells; CHEMBL3308243
DR   ChEMBL-Targets; CHEMBL2366198
DR   Cosmic; 787464
DR   Cosmic; 908451
DR   Cosmic; 975286
DR   Cosmic; 1281342
DR   Cosmic; 1523827
DR   Cosmic; 1524839
DR   Cosmic; 2131550
DR   Cosmic; 2297030
DR   Cosmic; 2306229
DR   Cosmic-CLP; 908451
DR   DepMap; ACH-000168
DR   DSMZ; ACC-542
DR   DSMZCellDive; ACC-542
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 908451
DR   GEO; GSM236799
DR   GEO; GSM236835
DR   GEO; GSM482496
DR   GEO; GSM887458
DR   GEO; GSM888538
DR   GEO; GSM1374774
DR   GEO; GSM1446755
DR   GEO; GSM1670283
DR   IARC_TP53; 21588
DR   JCRB; IFO50474
DR   LiGeA; CCLE_531
DR   LINCS_LDP; LCL-1074
DR   PharmacoDB; NOMO1_1165_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1609
DR   PubChem_Cell_line; CVCL_1609
DR   Wikidata; Q54930898
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.3960/jslrt1961.28.19;
RX   PubMed=1699657;
RX   PubMed=1701357;
RX   PubMed=9738977;
RX   PubMed=14671638;
RX   PubMed=20164919;
RX   PubMed=21552520;
RX   PubMed=22460905;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=28109323;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 55 hours (PubMed=25984343); ~35 hours (DSMZ=ACC-542).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=14671638).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.730-10T>C; dbSNP=rs201058616; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.4%; Native American=0.99%; East Asian, North=76.88%; East Asian, South=20.48%; South Asian=0%; European, North=0.98%; European, South=0.27% (PubMed=30894373).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,10
ST   D16S539: 9,11
ST   D18S51: 17,21.2 (DSMZ)
ST   D18S51: 17,22 (PubMed=25877200)
ST   D19S433: 13,14
ST   D21S11: 29,32.2
ST   D2S1338: 17,23
ST   D3S1358: 15,17
ST   D5S818: 11,13
ST   D7S820: 8,10
ST   D8S1179: 13,14
ST   FGA: 21,22
ST   Penta D: 9,12
ST   Penta E: 15,17
ST   TH01: 6,9
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C8263; Adult acute monocytic leukemia
DI   ORDO; Orphanet_514; Acute monoblastic/monocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   31Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   DOI=10.3960/jslrt1961.28.19;
RA   Ogura M., Hamaguchi M.;
RT   "Coagulation and fibrinolysis system of a human monocytic leukemia
RT   cell line, NOMO-1.";
RL   Nihon Monaikei Gakkai Kaishi 28:19-26(1988).
//
RX   PubMed=1699657;
RA   Towatari M., Ito Y., Morishita Y., Tanimoto M., Kawashima K.,
RA   Morishima Y., Andoh T., Saito H.;
RT   "Enhanced expression of DNA topoisomerase II by recombinant human
RT   granulocyte colony-stimulating factor in human leukemia cells.";
RL   Cancer Res. 50:7198-7202(1990).
//
RX   PubMed=1701357;
RA   Morishita Y., Kataoka T., Towatari M., Ito T., Inoue H., Ogura M.,
RA   Morishima Y., Saito H.;
RT   "Up-regulation of transferrin receptor gene expression by granulocyte
RT   colony-stimulating factor in human myeloid leukemia cells.";
RL   Cancer Res. 50:7955-7961(1990).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=14671638; DOI=10.1038/sj.leu.2403236;
RA   Drexler H.G., Quentmeier H., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   MLL gene alterations.";
RL   Leukemia 18:227-232(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169;
RA   Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A.,
RA   Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P.,
RA   Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.;
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:E19169-E19169(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28109323; DOI=10.1186/s13045-017-0396-0;
RA   Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A.,
RA   Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M.,
RA   Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.;
RT   "Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion
RT   gene.";
RL   J. Hematol. Oncol. 10:26.1-26.5(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//